Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets.

The transaction is structured such that Lōkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack’s public market platform to support long-term growth and access to capital.

The combined organization integrates Lōkahi Therapeutics’ dual-engine model - its late-stage clinical development program and ai²-driven asset sourcing and advancement platform - with Glucotrack’s existing technology infrastructure to create a scalable, repeatable framework for value creation.

In connection with the closing, Lōkahi Therapeutics securityholders received a combination of Glucotrack common stock and convertible preferred stock.

Upon receipt of required stockholder approvals and satisfaction of applicable Nasdaq listing requirements, the preferred stock is expected to convert into common equity, resulting in Lōkahi Therapeutics securityholders holding approximately 90% of the combined company on a fully diluted basis, subject to transaction-related financing and customary adjustments.